Display options
Cite
Song J, Xue YQ, Zhao MM, et al. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. Onco Targets Ther. 2018;11:3435-3439doi: 10.2147/OTT.S160685.
Song, J., Xue, Y. Q., Zhao, M. M., & Xu, P. (2018). Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. OncoTargets and therapy, 113435-3439. https://doi.org/10.2147/OTT.S160685
Song, Jie, et al. "Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis." OncoTargets and therapy vol. 11 (2018): 3435-3439. doi: https://doi.org/10.2147/OTT.S160685
Song J, Xue YQ, Zhao MM, Xu P. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. Onco Targets Ther. 2018 Jun 13;11:3435-3439. doi: 10.2147/OTT.S160685. eCollection 2018. PMID: 29942135; PMCID: PMC6005326.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2018 Jun 13;11:3435-3439. doi: 10.2147/OTT.S160685. eCollection 2018.

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis.

OncoTargets and therapy

Jie Song, Yue-Qin Xue, Ming-Ming Zhao, Peng Xu

Affiliations

  1. Department of Neurosurgery, Linyi Central Hospital, Linyi, People's Republic of China.
  2. Department of Pharmacy, Linyi Central Hospital, Linyi, People's Republic of China.
  3. Department of Cardiology, Linyi Central Hospital, Linyi, People's Republic of China.

PMID: 29942135 PMCID: PMC6005326 DOI: 10.2147/OTT.S160685

Abstract

BACKGROUND: Glioblastomas (GBMs) are the most aggressive type of glial brain tumors. Despite aggressive treatment with surgery and chemoradiation, GBMs invariably relapse and tumors are progressive. Controversy remains on optimal treatment of patients with recurrent GBMs. Data from previous trials have suggested that the addition of bevacizumab (BEV) to lomustine (CCNU) might improve overall survival (OS) as compared with that with monotherapies. The aim of this study was to compare the efficacy of BEV in addition to CCNU versus single-agent therapy in patients with recurrent GBM.

METHODS: Electronic databases were searched for eligible literature updated in December 2017. Trials assessing the effectiveness of CCNU and BEV in progressive GBM were included, of which the main outcomes were progression-free survival (PFS) and OS. All the data were pooled with the corresponding 95% confidence intervals (CIs) using RevMan software. Sensitivity and heterogeneity were quantitatively evaluated.

RESULTS: Three randomized clinical trials were identified, including 574 patients (combination group: 358, monotherapies group: 216). The combination group treated with BEV and CCNU showed improvement in PFS (OR = 0.49; 95% CI, 0.41-0.59;

CONCLUSION: Although treatment with CCNU plus BEV prolonged PFS, it did not confer OS advantage over monotherapies in patients with progressive GBM. The encouraging results of the addition of CCNU to BEV warrant investigation in further randomized trials.

Keywords: bevacizumab; brain tumors; glioblastoma; lomustine; meta-analysis; progression free survival

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. J Clin Oncol. 2010 Mar 1;28(7):1168-74 - PubMed
  2. Trials. 2007 Jun 07;8:16 - PubMed
  3. J Clin Oncol. 2013 Sep 10;31(26):3212-8 - PubMed
  4. Stat Med. 2002 Jun 15;21(11):1539-58 - PubMed
  5. Cancer. 2011 Dec 1;117(23 ):5351-8 - PubMed
  6. Curr Opin Neurol. 2009 Dec;22(6):633-8 - PubMed
  7. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  8. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  9. N Engl J Med. 2015 Jun 25;372(26):2481-98 - PubMed
  10. Cancer. 2015 Apr 1;121(7):997-1007 - PubMed
  11. Crit Rev Oncol Hematol. 2017 Mar;111:94-102 - PubMed
  12. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  13. J Neurooncol. 2016 Feb;126(3):567-75 - PubMed
  14. Cancer Res. 2016 Feb 1;76(3):525-34 - PubMed
  15. Cancer Cell. 2010 May 18;17(5):510-22 - PubMed
  16. Cancer Cell. 2007 Jan;11(1):83-95 - PubMed
  17. Arch Immunol Ther Exp (Warsz). 2013 Feb;61(1):25-41 - PubMed
  18. Lancet Oncol. 2014 Aug;15(9):943-53 - PubMed
  19. Neuro Oncol. 2014 Jun;16(6):815-22 - PubMed
  20. Cancer Res. 2001 Mar 15;61(6):2744-50 - PubMed
  21. N Engl J Med. 2017 Nov 16;377(20):1954-1963 - PubMed
  22. Arch Pathol Lab Med. 2008 Jun;132(6):906 - PubMed
  23. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  24. J Neurooncol. 2011 Jun;103(2):371-9 - PubMed
  25. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed

Publication Types